Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Advanced Therapies
Sort By
Newest First
1 / 1
1 / 1
Protein Degradation
PROTACS: Upgrading Small Molecule Inhibitors
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-24-NI-02
June 11, 2024
Biopharma Facility Design
Growing a Global Presence with a Continued Focus on Life Sciences Facilities
Arcadis DPS Group
PAO-02-23-PATV-03
February 16, 2023
Immuno-Oncology
Building Multiple Platforms to Address Difficult-to-Treat Cancers
Derek Hennecke
Inceptor Bio
PAO-05-22-R250-09
May 24, 2022
Pharma's Almanac
The Evolution and the Future of Pharma
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-22-R250-07
March 08, 2022
Cell and Gene Therapy
Realizing the Promise of Cell and Gene Therapy with an Advanced Manufacturing Platform
Shailesh Maingi; Mike Nicholson, Ph.D.
Inceptor Bio
PAO-01-22-R250-15
January 31, 2022
Cell Therapy
Enabling Novel Cell Therapies by Leveraging Established Blood Stem Cell Transplant Infrastructure
Chris McClain
Be The Match BioTherapies
PAO-09-21-CL-04
September 09, 2021
mRNA Therapies
Realizing the Promise of RNA Therapies with Lipid Nanoparticle Delivery
Shiksha Mantri, Ph.D.
MilliporeSigma
PAO-06-21-CL-08
June 16, 2021
Cell and Gene Therapy
Expanding a Comprehensive Platform to Support the Future of Cell and Gene Therapies
David Y. H. Chang, Ph.D.
WuXi Advanced Therapies
PAO-05-21-CL-05
May 27, 2021
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
Pharma's Almanac
PAO-03-21-NI-01
March 16, 2021
Cell and Gene Therapy
Advanced Therapies: Landscape, the Road Forward, and M&A
Thomas Isett
i.e. Advising
PAP-Q2-2019-CL-021
May 24, 2019